Search…

Xinlitai (002294.SZ): application for clinical trial of self-developed innovative small molecule drug SAL0140 tablets has been accepted.

28/08/2025

Financial APP news, Xinlitai (002294.SZ) announced that the company has recently received an acceptance notification issued by the National Medical Products Administration. The clinical trial application for the company's innovative small molecule drug SAL0140 tablet (project code: SAL0140) has been accepted.

Latest

2 m ago

Macquarie analyst Adya Suresh has given a rare "sell" rating to the top Indian delivery companies Eternal Corp and Swiggy, warning that high valuations and thin profit margins could limit upside potential. Suresh expects Eternal Corp's stock price to potentially drop by 40% in the next year, while Swiggy may face a 35% decline.

2 m ago

Andawell (300719.SZ) released its first half-year performance, turning from profit to loss with a loss of 11.9131 million yuan.

2 m ago

Zhongxin Shares (603091.SH) released its semi-annual performance, with a net profit attributable to the parent company of 116 million yuan, a year-on-year decrease of 14.76%.

3 m ago

Crown City Watch, Clock and Jewelry (00256.HK) announced its interim financial results. The company reported a loss of HKD 42.045 million, a year-on-year change from profit to loss.

3 m ago

Analysts believe that India's dense urban layout, low labor costs, and rapidly growing digital consumer base of over 730 million could support this business model, which has faced obstacles in other regions - even though these companies have accumulated losses of over 1.4 billion US dollars in the past four years.

See all latest